Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx (NYSE AMERICAN: VNRX) has published findings from three large, independent studies conducted in France, Germany, and the Netherlands, involving over 3,000 sepsis patients. The studies demonstrate that their Nu.Q® NETs test could predict patients at higher risk of deteriorating from sepsis by measuring levels of circulating H3.1 nucleosomes in the bloodstream. Research shows that elevated H3.1 levels are associated with increased risk of mortality, renal failure, respiratory failure, multi-organ failure, and septic shock. The company is currently seeking to commercialize Nu.Q® NETs and using these study findings to support licensing discussions with industry stakeholders.
VolitionRx (NYSE AMERICAN: VNRX) is participating in a webinar hosted by Edison Group to discuss new data on the potential use of Nu.Q® NETs in sepsis management. The data, presented at ESICM LIVES 2024, includes three independent studies involving over 3000 patients and more than 14,000 patient samples. The webinar, scheduled for October 21, 2024, at 10:00 AM ET, will feature updates from Volition's Chief Medical Officer and Chief Commercial Officer.
The presentation will focus on the role of H3.1 nucleosomes in NETosis, the implications of elevated H3.1 levels in sepsis patients, and the potential of Nu.Q® NETs biomarker to predict organ failure. Volition's Nu.Q® NETs technology quantifies circulating H3.1 nucleosomes in the bloodstream, serving as a surrogate marker for Neutrophil Extracellular Traps (NETs). The company aims to develop simple, cost-effective blood tests for diagnosing and monitoring various diseases, including cancer, in both humans and animals.
VolitionRx (NYSE AMERICAN: VNRX) is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024. The session, titled 'NETs: Casting a new light on sepsis management', will feature experts presenting findings from large, independent studies on using Nu.Q® NETs to enhance sepsis management.
Professor Djillali Annane, chair of the symposium, highlights the potential of Nu.Q® NETs H3.1 assay in clinical practice for sepsis management. The symposium will explore the role of H3.1 nucleosomes in NETosis, the clinical utility of H3.1 in recent large-scale studies, and how Nu.Q® NETs biomarker could predict organ failure.
Nu.Q® NETs is Volition's technology that quantifies circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs). Elevated levels of NETs can lead to tissue damage, sepsis, organ failure, and death.
VolitionRx (NYSE AMERICAN: VNRX) has appointed Dr. Ethel Rubin as an independent director to its board, effective September 30, 2024. Dr. Rubin, with over 20 years of experience in the life sciences sector, will also serve on the Audit and Compensation Committees. Her extensive background includes leadership roles at BioFortis, CSA Medical, Medtronic, and currently as Head of Ventures at BioHealth Innovation.
Guy Innes, Interim Chair of Volition, highlighted Dr. Rubin's vast knowledge of the life sciences industry and her contribution to launching over 25 commercial products. Dr. Rubin expressed excitement about joining Volition, noting the potential of the company's Nu.Q® technology in both animal and human health sectors, particularly for early detection and monitoring of diseases like cancer and sepsis.
VolitionRx (NYSE AMERICAN: VNRX) hosted a Key Opinion Leader (KOL) roundtable in Paris to explore the potential of its Nu.Q® NETs technology in sepsis management. The event, chaired by Professor Djillali Annane, brought together leading sepsis experts worldwide. Discussions revealed that Nu.Q® NETs could potentially predict organ failure, such as acute kidney injury, in patients with infection, enhancing sepsis management.
Nu.Q® NETs quantifies circulating H3.1 nucleosomes in the bloodstream, a marker for Neutrophil Extracellular Traps (NETs). While NETs are important for immune response, elevated levels can lead to tissue damage and, in severe cases, sepsis and organ failure. Volition plans to share latest findings at an upcoming symposium at ESICM in Barcelona on October 7, 2024.
VolitionRx (NYSE AMERICAN: VNRX) announced its Q2 2024 financial results and business update. Key highlights include:
- Expanded access to Nu.Q® Vet Cancer Test to 17 countries
- Sold over 60,000 Nu.Q® Vet Cancer Tests in H1 2024, surpassing full-year 2023 sales
- Engaged in commercial discussions for potential licensing opportunities
- Q2 2024 revenue up 83% year-over-year at $396,000
- H1 2024 revenue up 55% year-over-year at $567,000
- Implemented cost reduction measures targeting $10 million in annualized savings
- Cash and cash equivalents of $6.0 million as of June 30, 2024
- Completed a $7 million registered direct offering with potential for additional $14.5 million
The company is focusing on securing its first licensing deal in the human space in H2 2024.
VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering of up to $21.5 million. The offering includes 12,727,273 shares of common stock (or equivalents) and milestone-linked warrants at $0.55 per share. H.C. Wainwright & Co. is the exclusive placement agent. The initial gross proceeds are expected to be $7 million, with potential additional proceeds of $14.5 million if all warrants are exercised. The offering is set to close around August 12, 2024. Funds will be used for research, product development, clinical studies, commercialization, and working capital. The offering is made under a shelf registration statement filed with the SEC.
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Thursday, August 15, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2024 and provide a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, and Dr. Andrew Retter. Participants can join via phone or listen to a live audio webcast on Volition's investor relations website. A replay of the call will be available until August 29, 2024. This event provides an opportunity for investors and analysts to gain insights into Volition's recent performance and future outlook.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, has enlisted PharmaVentures to provide strategic advice and support for licensing its oncology portfolio, including Nu.Q® Cancer and Capture-PCR™ technologies. The collaboration aims to secure licensing deals with industry leaders. Volition's technologies focus on simple, cost-effective blood-based assays to detect, guide treatment, and monitor cancer. Gael Forterre, Chief Commercial Officer of Volition, highlighted PharmaVentures' expertise in deal-making, while PharmaVentures' MD Adrian Dawkes expressed optimism about the potential of Volition's epigenetic technology to improve patient outcomes globally.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, has issued a mid-year review before its Annual Meeting on July 2, 2024. The review highlights the expansion of the Nu.Q® Vet Cancer Test to 15 countries, ongoing commercial discussions with major players in liquid biopsy, IVD, sepsis, and oncology, and preparation for potential near-term licensing opportunities. CEO Cameron Reynolds emphasized significant progress in 2024, including supporting veterinary partners and advancing Nu.Q® NETs for sepsis, Nu.Q® Lung Cancer, and Capture-PCR™ technologies toward licensing. With substantial study data nearing readiness, Volition aims to negotiate its first human-space licensing deal in the second half of 2024.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
What does VolitionRx Limited do?
Where is VolitionRx Limited based?
What is the Nu.Q® Vet Cancer Test?
What are VolitionRx's recent achievements?
What is the Nucleosomics™ platform?
How is VolitionRx planning to achieve cash flow neutrality by 2025?
How can I get more information about VolitionRx?
What diseases does VolitionRx target with its tests?
What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?
What upcoming milestones does VolitionRx expect?
